Table 2.
Quantification of SARS-CoV-2 S antibody positivity of individuals given 2 doses of Sinopharm vaccine.
| Group | Age (years) | Sex | Negative | Positive | Spike antibody levels (U/mL) | ||||
|---|---|---|---|---|---|---|---|---|---|
| No (%)* | No other clinical issues (%)** | No (%)* | No other clinical issues (%)** | Median | Minimum | Maximun | |||
| 1 | <20 | Female | 0 | 0 | 1 (100) | 0 | 85.82 | 85.82 | 85.82 |
| Male | 0 | 0 | 3 (100) | 0 | 180.68 | 42.05 | 250 | ||
| 2 | 20-30 | Female | 0 | 0 | 22 (100) | 1 (4.5) | 183.97 | 14.97 | 250*** |
| Male | 1 (2.9) | 1 (100) | 34 (97.1) | 2 (5.9) | 167.59 | 0.4 | 250*** | ||
| 3 | 31-<50 | Female | 2 (3) | 1 (50) | 65 (97) | 4 (6.2) | 154.54 | 0.41 | 250*** |
| Male | 7 (6.9) | 4 (57.1) | 95 (93.1) | 0 | 132.92 | 0.4 | 250*** | ||
| 4 | >50 | Female | 2 (2.7) | 1 (50) | 71 (97.3) | 11 (15.5) | 98.17 | 0.4 | 250*** |
| Male | 3 (3.9) | 2 (66.7) | 73 (96.1) | 7 (9.6) | 90.01 | 0.4 | 250*** | ||
| Total | 15 (4) | 9 (60) | 364 (96) | 25 (6.9) | 136.71 | 0.4 | 250 | ||
*Percentage of donors with negative/positive spike values of female/male in that group.
**Percentage of donors with negative/positive spike values with other clinical issues of female/male in that group.
***Some donors in this group had spike antibody levels >250 U/mL.